Search results for "TRANSFUSION"

showing 10 items of 177 documents

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with adv…

2012

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy. Patients and Methods Twenty-nine patients with HER2-positive breast cancer whose d…

OncologyCancer ResearchReceptor ErbB-2MESH: Risk AssessmentMESH: Dose-Response Relationship Drug0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesProspective cohort studyskin and connective tissue diseasespertuzumab; trastuzumab; breast cancerMESH: Treatment OutcomeMESH: Aged0303 health sciencesMESH: Middle AgedMESH: ErythrocytesAge FactorsMESH: Maximum Tolerated DoseMESH: Neoplasm StagingMiddle AgedPrognosis3. Good healthtrastuzumabMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeOncologyTolerabilityMESH: Receptor erbB-2030220 oncology & carcinogenesisMESH: Survival AnalysisDisease Progression[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Disease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaximum Tolerated DoseMESH: Blood TransfusionBreast NeoplasmsMESH: Drug Administration ScheduleAntibodies Monoclonal HumanizedLoading doseMESH: Cell SeparationRisk AssessmentMESH: PrognosisDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesbreast cancerBreast cancerMESH: PrionspertuzumabInternal medicineHumansMESH: Patient SelectionNeoplasm InvasivenessneoplasmsSurvival analysis030304 developmental biologyAgedNeoplasm StagingMESH: Age FactorsMESH: HumansDose-Response Relationship Drugbusiness.industryPatient SelectionMESH: AdultMESH: Neoplasm InvasivenessMESH: Creutzfeldt-Jakob SyndromeTrastuzumabmedicine.diseaseSurvival AnalysisMESH: Prospective StudiesMESH: Antibodies Monoclonal HumanizedMESH: Disease-Free SurvivalbusinessMESH: FemaleProgressive diseaseMESH: Breast NeoplasmsJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocy…

2018

Relapse of acute leukemia (AL) after allogeneic hematopoietic cell transplantation (Allo-HCT) entails a dismal prognosis. In this scenario, donor lymphocyte infusions (DLIs) and second Allo-HCT are two major approaches. We compared outcomes of AL patients treated for relapse with DLI or second Allo-HCT after receiving debulking therapy. In total, 46 patients were included in the study; 30 (65%) had acute myeloid leukemia and 16 (35%) had acute lymphoblastic leukemia. The median age was 38 years (range 4-66). Twenty-seven patients received a second Allo-HCT and 19 patients received DLI. The median follow-up of the cohort was 273 days (range 9-7013). Overall survival (OS), disease-free surviv…

OncologyMaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationKaplan-Meier EstimateCohort Studies0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceChildAcute leukemiaUnivariate analysisHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaAllograftsLeukemiaLeukemia Myeloid Acutesurgical procedures operative030220 oncology & carcinogenesisChild PreschoolLymphocyte TransfusionFemaleLeukocyte Reduction ProceduresAdultmedicine.medical_specialtyAdolescentGraft vs Leukemia EffectDisease-Free Survival03 medical and health sciencesYoung AdultInternal medicineGeneticsmedicineHumansMolecular BiologyAgedRetrospective StudiesImmunosuppression TherapySalvage Therapybusiness.industryCell Biologymedicine.diseaseTransplantationbusiness030215 immunologyExperimental hematology
researchProduct

T-Zelltherapien in der Onkologie

2002

OncologyTransplantationVaccinationmedicine.medical_specialtymedicine.anatomical_structurebusiness.industryInternal medicineT cellmedicineGeneral MedicineStem cellbusinessAllogeneic transfusionDMW - Deutsche Medizinische Wochenschrift
researchProduct

Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman Disease

2006

Oncologymedicine.medical_specialtyBlood transfusionbiologybusiness.industryBortezomibmedicine.medical_treatmentCastleman diseaseTreatment outcomeHematologymedicine.diseaseCytokineText miningInternal medicinemedicinebiology.proteinMulticentric Castleman DiseaseInterleukin 6businessmedicine.drugBritish Journal of Haematology
researchProduct

Transfusion-associated graft-versus-host disease-report of two further cases with an immunohistochemical analysis

1994

Summary Transfusion-associated graft-vs.-host disease (tGVHD) is a severe disease usually affecting immunocompromised hosts with haematological neoplasia. Two patients with acute leukaemia are reported, who developed fatal tGVHD after blood transfusions. Intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and endothelial leucocyte adhesion molecule 1 (ELAM-1) expression and the CD4/CD8 ratio were assessed in lesional skin. ICAM-1 was strongly expressed on epidermal keratinocytes and endothelial cells (EC) and correlated with HLA-DR staining. VCAM-1 was strongly expressed on EC in the superficial dermal vessels. ELAM-1 stained weakly on EC in some of the su…

Pathologymedicine.medical_specialtyBlood transfusionCD3medicine.medical_treatmentIntercellular Adhesion Molecule-1CD4-CD8 RatioGraft vs Host DiseaseVascular Cell Adhesion Molecule-1CD18DermatologyTransfusion-associated graft versus host diseaseFatal OutcomeHumansLeukemia-Lymphoma Adult T-CellMedicineSkinbiologybusiness.industryCell adhesion moleculeTransfusion ReactionMiddle AgedIntercellular Adhesion Molecule-1medicine.diseaseLeukemia Myeloid AcuteLeukemiaImmunologybiology.proteinFemalebusinessCell Adhesion MoleculesCD8Clinical and Experimental Dermatology
researchProduct

Serum antibodies to thymus epithelial cells in non-A, non-B and cryptogenic chronic liver disease

2008

Antibodies against thymus epithelial cells (anti-TEC) and the basal cell layer (BCLA) of squamous epithelia have been described in association with HDV-related chronic liver disease (CLD). Data are lacking on their presence during nAnB virus infection. Sera from 51 patients with nAnB post-transfusion hepatitis, including acute and chronic cases diagnosed during a prospective study on candidates for cardiac surgery, and 167 with various forms of CLD were tested for the presence of anti-TEC and BCLA using indirect immunofluorescence on human thymus and rat forestomach sections. Both antibodies mainly occurred in nAnB, HDV and cryptogenic CLD (anti-TEC: 51%, 47% and 42%; BCLA: 29%, 38% and 31%…

Pathologymedicine.medical_specialtyHepatitis Viral Humanmedicine.drug_classFluorescent Antibody TechniqueThymus GlandChronic liver diseaseMonoclonal antibodyEpitheliumSerologyPrimary biliary cirrhosisAntigenAntibody SpecificitymedicinePrevalenceHumansProspective StudiesChildAutoantibodiesHepatitis ChronicHepatitisHepatologybiologyLiver DiseasesAutoantibodyAntibodies MonoclonalTransfusion Reactionmedicine.diseaseHepatitis CImmunologyAcute Diseasebiology.proteinKeratinsAntibody
researchProduct

Accuracy of blood transfusion in postpartum hemorrhage to assess maternal morbidity.

2012

International audience; OBJECTIVE: To measure the accuracy of blood transfusion (timing and number of blood units) in postpartum hemorrhage (PPH) in a perinatal network. STUDY DESIGN: (1) The ANONYMAT software system was used for anonymization and linkage of two large stand-alone databases, the Burgundy Perinatal Network (BPN) and the National Blood Centre (EFS) databases, which contain, respectively, clinical data from hospital discharges and information concerning any blood transfusion in France (considered as the gold standard database for identifying any transfusion). (2) Identification of prescriptions of at least one red blood cell (RBC) unit at the day of delivery (≥22 weeks) and up …

PediatricsBlood transfusionmedicine.medical_treatment0302 clinical medicineMESH: PregnancyBlood productPregnancyPerinatal networkMESH : Blood Transfusion[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Female030212 general & internal medicineMESH : Obstetrics030219 obstetrics & reproductive medicineObstetricsMedical recordObstetrics and GynecologyMESH: Postpartum HemorrhageMESH: Predictive Value of Tests3. Good healthObstetricsBlood units[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleFranceMESH : Sensitivity and SpecificityMESH: Obstetricsmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaternal morbidityMESH: Blood TransfusionMESH : Postpartum HemorrhageSensitivity and Specificity03 medical and health sciencesPredictive Value of TestsmedicineHumansBlood TransfusionMESH : Predictive Value of TestsMedical prescriptionMESH : FranceMESH: Humansbusiness.industryPostpartum HemorrhageMESH : HumansGold standard (test)MESH: Sensitivity and SpecificityMESH: FranceMESH : PregnancyReproductive MedicinebusinessMESH: Female
researchProduct

Erythropoietin and iron therapy for preterm infants

1999

Pediatricsmedicine.medical_specialtyBlood transfusionmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentHematocritPhlebotomyInfant newbornErythropoietinPediatrics Perinatology and Child HealthmedicinebusinessIron therapymedicine.drugThe Journal of Pediatrics
researchProduct

Mild twin–twin transfusion syndrome: Clinical report.

2008

Pediatricsmedicine.medical_specialtyClinical reportbusiness.industryPediatrics Perinatology and Child HealthTransfusion twinsmedicineObstetrics and GynecologybusinessTwin Twin Transfusion Syndrome
researchProduct

Transfusion‐transmitted malaria of plasmodium malariae in palermo, sicily

2021

Transfusion-transmitted malaria (TTM) is a rare occurrence with serious consequences for the recipient. In non-endemic areas, the incidence of transmission of malaria by transfusion is very low. We report a clinical case of transfusion-transmitted malaria due to Plasmodium malariae, which happened in a patient with acute hemorrhagic gastropathy. Case presentation: In April 2019, a 70-year-old Italian man with recurrent spiking fever for four days was diagnosed with a P. malariae infection, as confirmed using microscopy and real-time PCR. The patient had never been abroad, but about two months before, he had received a red blood cell transfusion for anemia. Regarding the donor, we revealed t…

Pediatricsmedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaBlood transfusionLeadership and ManagementAnemiamedicine.medical_treatmentmalariaCase ReportthrombocytopeniaHealth InformaticsPlasmodium malariaeParasitemiablood transfusionblood donor screeningAsymptomaticPlasmodium malariaetransfusion-transmitted malariaHealth Information ManagementAsymptomatic semi‐immune donors Blood donor screening Blood transfusion Malaria Plasmodium malariae Thrombocytopenia Transfusion-transmitted malaria<i>Plasmodium malariae</i>parasitic diseasesmedicinebiologybusiness.industryHealth PolicyIncidence (epidemiology)Rbiology.organism_classificationmedicine.diseaseDiagnosis of malariaasymptomatic semi-immune donorsMedicinemedicine.symptombusinessMalaria
researchProduct